SOFINNOVA-PARTNERS
14.10.2020 08:02:10 CEST | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Dr. Joe Anderson as Partner in the Sofinnova Crossover Fund, effective immediately.
Dr. Anderson has over 25 years’ experience in the healthcare and life sciences industries. Previously, he was a Partner at Abingworth LLP for over a decade, where he led venture-style investments in public companies and the formation of the firm’s public equities fund. Most recently, Dr. Anderson was Co-Founder and Chief Executive Officer at Arix Bioscience plc, a venture capital firm listed on the London Stock Exchange.
Dr. Anderson has substantial experience as an active Board Member developing innovative life sciences companies in the UK and the US and his investments have involved numerous private and public financing rounds, IPOs, M&As and exits.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, commented: “Joe’s arrival signals a decisive moment of growth for the Sofinnova Crossover Fund. It comes on the heels of a number of recent milestones, including two IPOs on the Nasdaq, new investments, positive clinical data and key appointments in our portfolio companies. His extensive experience leading venture capital investments in private and public companies will allow us to continue building on the great work of the Crossover team and positions Sofinnova Partners for further expansion.”
Joe Anderson commented: “I am delighted to join Sofinnova Partners at this exciting time for life sciences in Europe. The firm has been a pioneer in life sciences investing, most recently through the founding of the Sofinnova Crossover Fund -- one of the first of its kind in Europe. Record numbers of companies are being formed from a flourishing science base in Europe. Access to later-stage scale-up capital is crucial as they seek to build and retain value and the need for this kind of investment has never been greater. I look forward to working with my colleagues to further develop this leading European strategy.”
Jacques Theurillat, Partner in the Sofinnova Crossover Fund, commented: “We warmly welcome Joe to the Sofinnova Crossover team. Joe’s knowledge and expertise will further reinforce our experienced team of investment partners, Kinam Hong, Cédric Moreau, Tom Burt and myself, as we support ground-breaking innovations and enable later-stage life sciences companies to reach their full potential.”
Dr. Anderson began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became Head of the strategy group. He then moved to the City as a pharmaceuticals analyst at Dresdner Kleinwort Benson, before being appointed Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. He then joined Abingworth LLP as a Partner for 12 years before moving on to co-found Arix Biosciences in 2016 and lead its IPO on the London Stock Exchange the following year. He holds a Ph.D. in Biochemistry.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005998/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KiddeFenwal Launches New Website and Information Hub8.7.2026 18:00:00 CEST | Press release
Enhanced digital platform reflects KiddeFenwal’s legacy, stature and growth trajectory in the fire suppression and safety controls industry KiddeFenwal, the global leader in the fire suppression and safety controls industry, today unveiled a revitalized website, designed to serve as a comprehensive information hub for fire industry practitioners and customers alike. The modernized platform includes features created specifically with the company’s global partners, OEMs and distributors in mind, including: Accelerated asset navigation, pointing users to critical safety documentation, design parameters and product specifications; Seamless solution mapping, helping users quickly locate fire suppression configurations by industry, from data centers to BESS applications to commercial kitchens; and Enhanced resource access, including streamlined pathways to connect with the company’s elite distributor network across 120 countries. It also provides information about the company’s three brands,
Dryad Networks Reaches XPRIZE Wildfire Finals Milestone, Demonstrating Autonomous Detection and Suppression of Wildfires in Alaska8.7.2026 17:00:00 CEST | Press release
Dryad Networks, the leader in ultra-early wildfire detection technology, today announced a major achievement in the finals of the Autonomous Wildfire Response track of XPRIZE Wildfire, a four-year, $11 million global competition accelerating new solutions to end destructive wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707802818/en/ The Silvaguard Suppression Drone can deliver a 100 liter liquid suppressant to autonomously suppress small wildfires detected by Silvanet Competing against just two other finalists selected from an original field of nearly 300 teams worldwide, Dryad successfully demonstrated the integrated capabilities of its Silvanet wildfire detection network and Silvaguard autonomous firefighting drone system during final testing in remote Alaska. The XPRIZE Wildfire finals challenged teams to autonomously detect and suppress a wildfire without any human intervention across a vast 1,000 square k
Rigaku Opens "Rigaku Solutions Center Osaka" to Strengthen Global Semiconductor Metrology Service Capabilities8.7.2026 17:00:00 CEST | Press release
- Centralizing and Expanding Practical Training to Strengthen Global Service Capabilities - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), has opened the Rigaku Solutions Center Osaka (RSC-Osaka) at its Osaka Plant. The new facility centralizes and expands practical training for field service engineers supporting semiconductor metrology systems, strengthening Rigaku's global service capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708402770/en/ Photo: Hands-on training using the TXRF-V310 at RSC-Osaka As semiconductor manufacturing processes continue to advance toward finer geometries, higher layer counts, and more complex three-dimensional structures, semiconductor metrology systems require ever greater precision and operational stability. X-ray analytical technologies pl
Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®8.7.2026 16:05:00 CEST | Press release
New data highlight multi-center 5-year durability, 10-year survival, and the largest single-center experience across both HFrEF and HFpEF patients with functional mitral regurgitation Cardiac Dimensions, a leader in transcatheter therapies for heart failure, today announced the publication of three major manuscripts that together form the most comprehensive evidence base ever assembled for transcatheter indirect mitral annuloplasty. These publications span a five-year multi-center commercial registry, the largest single-center experience across both preserved and reduced ejection fraction, and long-term survival results through ten years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707656796/en/ Carillon Mitral Contour System® The Carillon Mitral Contour System is the only commercially available indirect mitral annuloplasty device, designed to treat a broad and expanding population of patients living with functional mi
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom